<aside> <img src="https://s3-us-west-2.amazonaws.com/secure.notion-static.com/c4781324-da52-45f4-9b81-426253a3dcd0/address-book.png" alt="https://s3-us-west-2.amazonaws.com/secure.notion-static.com/c4781324-da52-45f4-9b81-426253a3dcd0/address-book.png" width="40px" /> Comment on Notion, email me [email protected], and DM me @lukassteinbock and for any questions, comments, and feedback.

</aside>

Nothing against these sub-spaces to group them all in the same section. I think they're hugely important in the space, but I'm honestly a little biased in my knowledge and interest.

Peer to Peer

• Peer-to-peer therapy has massive potential because of its ability to solve the supply and demand issue and its proven effectiveness. Fellow peers also provide lower costs, greater empathy, and more anonymity. Disadvantages include the potential lack of professionalism and clinical effectiveness.
• Resources: Mental Health America (MHA) conducted a study, proving that there were lower costs of services, lower re-hospitalization rates, and other benefits. See the study below and key takeaways from the study on the Solutions page.

Evidence for Peer Support May 2019 (2).docx

Addiction

• Addiction is another mental illness similarly treated with therapy and medication. While many clinics are currently for the wealthy, companies are trying to democratize access through virtual programs. The question is, do these virtual programs have the same effectiveness? Do you need some sort of in person treatment?
• There is also a lack of funding in this space compared to other categories. From Rock Health's latest research on this: In 2020, mental health startups had an average deal size of $28.4M, three times that of SUD companies ($9.2M) and two times that of DD companies ($14.1M) (thank you to Payal Parikh for the stat).

Severe Illness

• Treating diseases like Autism and Schizophrenia, the stakes are higher and the care must be more specialized. While the market for this is not as large as others, many lessons can be learned from insured Autism services where companies are looking to prove to payers that they are producing clinically viable outcomes.
• Note: For the purposes of consolidation and easy viewing, I have group severe illness companies into to therapy for my market map.

Digital Therapeutics

• Digital therapeutics (DTx) are in the business of treating digital mental health therapies like a drug, trying to get approval from the FDA. The Digital Therapeutics Alliance (DTA) works together (and lobbies) to get this done, while other companies like Pear Therapeutics take it upon themselves to get state reimbursement laws rewritten. Both of these efforts come with the goal of reimbursement. This space is still young, however, and Medicare and most state Medicaid plan do not cover DTx.
  • Freespira, by Freespira, Inc. (DTA)
  • reSET, by Pear Therapeutics (DTA)
  • reSET-O, by Pear Therapeutics (DTA)
  • [SOMRYST, by Pear Therapeutics](https://peartherapeutics.com/pear-therapeutics-obtains-fda-authorization-for-somryst-a-prescription-digital-therapeutic-for-the-treatment-of-adults-with-chronic-insomnia/#:~:text=today announced the U.S. Food,and older with chronic insomnia.)
  • EndeavorRx by Akili
• I've also added Levels, Oura, Whoop to this section although it might be considered to be more in the general health tech space. These companies are incredible helpful in terms of tracking outcomes, which you can read more about in the Solutions section.
  • Check out my podcast with Sam Corcos, their CEO, here to learn more about they track glucose levels to better your health.